20-Hydroxyeicosatetraenoic acid, endothelial dysfunction and hypertension

Medicinski Glasnik

Volumn 8, Issue 2, 2011, Pages 170-180

  Kunert, Mary Pat ^a   Drenjančević, Ines ^b  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^b JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

20 HETE; Endothelial dysfunction; Hypertension

Indexed keywords

20 HYDROXYEICOSA 6,15 DIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; CALCIUM CHANNEL L TYPE; CYCLIC GMP; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FORMAMIDINE; HEAT SHOCK PROTEIN 90; HET 0016; INDUCIBLE NITRIC OXIDE SYNTHASE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LISINOPRIL; LOSARTAN; MICONAZOLE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROTEIN INHIBITOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

CARDIOVASCULAR FUNCTION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY ACID SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY TUBULE; MASS FRAGMENTOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION; VASOCONSTRICTION; VASODILATATION; WESTERN BLOTTING;

CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 80051629820     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Gillespie C, Kuklina EV, Briss PA, Blair NA, Hong HY. Vital signs: prevalence, treatment, and control of hypertension---united states, 1999--2002 and 2005--2008. MMWR 2011; 60:103-8.
2. Yoon SS OY, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. NCHS data brief 2010:1-8.
3. Erceg M, Kern J, Babic-Ersig A, Ivicevic-Uhernik A, Vuletic S. Regional differences in the prevalence of arterial hypertension in Croatia. Coll Antropoll 2009; 33:19-23.
4. Félétou M KR, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: Possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 2010; 12:267-75.
5. Versari D, Daghini E, Virdis A, Ghiadonin L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157:527-36.
6. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-85.
7. Sun CW, Falck JR, Harder DR, Roman RJ. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 1999; 33:414-8.
8. Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, Roman RJ. 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. AJP 1996; 270:R228-37.
9. Ma YH, Gebremedhin D, Schwartzman ML, Falck JR, Clark JE, Masters BS, Harder DR, Roman RJ. 20-hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res 1993; 72:126-36.
10. Alonso-Galicia M, Falck JR, Reddy KM, Roman RJ. 20-HETE agonists and antagonists in the renal circulation. AJP 1999; 277:F790-6.
11. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. AJP 1996; 270:R217-27.
12. Sun CW, Alonso-Galicia M, Taheri MR, Falck JR, Harder DR, Roman RJ. Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res 1998; 83:1069-79.
13. Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, Laniado-Schwartzman M. Cyp4a1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SRH. AJP 2001; 280:R255-61.
14. Harder DR, Narayanan J, Birks EK, Liard JF, Imig JD, Lombard JH, Lange AR, Roman RJ. Identification of a putative microvascular oxygen sensor. Circ Res 1996; 79:54-61.
15. Kunert MP RR, Falck JR, Lombard JH. Differential effect of cytochrome p-450 Ω-hydroxylase inhibition on o2-induced constriction of arterioles in shr with early and established hypertension. Microcirculation 2001; 8:435-43.
16. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Oka-moto H, Roman RJ, Nithipatikom K, Campbell WB, Harder DR. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 2000; 87:60-5.
17. Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, Roman R. Formation and action of a p-450 4a metabolite of arachidonic acid in cat cerebral microvessels. AJP 1994; 266:H2098-107.
18. Lange A, Gebremedhin D, Narayanan J, Harder D. 20-hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem 1997; 272:27345-52.
19. 2+ current. J Physiol 1998; 507 (Pt3):771-81.
20. Cloutier M CS, Basora N, Proteau S, Payet MD, Rousseau E. 20-HETE inotropic effects involve the activation of a nonselective cationic current in airway smooth muscle. AJP 2003; 285:L560-8.
21. Hercule HC, Ovekan AO. Cytochrome p450 v/v-1 hydroxylase-derived eicosanoids contribute to endothelin A and endothelin B receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther 2000; 292:1153-60.
22. Sodhi K, Wu CC, Cheng J, Gotlinger K, Inoue K, Goli M, Falck JR, Abraham NG, Schwartzman ML. Cyp4a2-induced hypertension is 20-hydroxyeicosatetraenoic acid-and angiotensinII-dependent. Hyperension 2010; 56:871-8.
23. Raffai G, Wang J, Roman RJ, Anjaiah S, Weinberg B, Falck JR, Lombard JH. Modulation by cytochrome p450-4a omega-hydroxylase enzymes of adrenergic vasoconstriction and response to reduced pO2 in mesenteric resistance arteries of Dahl salt-sensitive rats. Microcirculation 2010; 17:525-35.
24. Ljuca F, Drevensek G. Endothelin-1 induced vascular smooth muscle cell proliferation is mediated by cytochrome p-450 arachidonic acid metabolites. Bosn J Basic Med Sci 2010; 10:223-6.
25. Imig JD. 20-hydroxyeicosatetraenoic acid and angiotensin: A positive feedback system to cause hypertension. Hypertension 2010; 56:822-3.
26. Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D, Schwartzman ML. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via ikappab kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010; 332:57-65.
27. Yousif MHM, Benter IF, Dunn KMJ, Dahly-Vernon AJ, Akhtar S, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes. Autonomic and Autacoid Pharmacology 2009; 29:1-12.
28. Wang J, Schmidt JR, Roman RJ, Anjaiah S, Falck JR, Lombard JH. Modulation of vascular o2responses by cytochrome 450-4a ω-hydroxylase metabolites in Dahl salt-sensitive rats. Microcirculation 2009; 16:345-54.
29. Guo AM, Scicli G, Sheng J, Falck JR, Edwards PA, Scicli AG. 20-HETE can act as a nonhypoxic regulator of HIF-1 in human microvascular endothelial cells. AJP 2009; 297:H602-13.
30. Berezan DJ, Xu Y, Falck JR, Kundu AP, Davidge ST. Ovariectomy, but not estrogen deficiency, increases cyp4a modulation of alpha(1)-adrenergic vasoconstriction in aging female rats. Am J Hypertens 2008; 21:685-90.
31. Benter IF, Yousif MH, Canatan H, Akhtar S. Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol Res 2005; 52:252-257.
32. Zhang F. Transfection of cyp4a1 cdna decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli. AJP 2004; 287:H1089-H95.
33. Wang J, Roman RJ, Falck JR, de la Cruz L, Lombard JH. Effects of high-salt diet on cyp450-4a -hydroxylase expression and active tone in mesenteric resistance arteries. AJP 2005; 288:H1557-H65.
34. Kaide JI. Vascular co counterbalances the sensitizing influence of 20-HETE on agonist-induced vasoconstriction. Hypertension 2004; 44:210-6.
35. Quilley J, Qiu Y, Hirt J. Inhibitors of 20-hydroxyeicosatetraenoic acid reduce renal vasoconstrictor responsiveness. J Pharmacol Exp Ther 2003; 307:223-9.
36. Kalyankrishna S, Malik KU. Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites genera-ted by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells. J Pharmacol Exp Ther 2003; 304:761-72.
37. Frisbee J. Parenchymal tissue cytochrome p450 4a enzymes contribute to oxygen-induced alterations in skeletal muscle arteriolar tone. Microvascular Res 2002; 63:340-3.
38. Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of rhokinase. Hypertension 2003; 41:801-806.
39. Ratz PH, Miner AS, Barbour SE. Calcium-independent phospholipase A2 participates in KCl-induced calcium sensitization of vascular smooth muscle. Cell Calcium 2009; 46:65-72.
40. Imaoka S HT, Funae Y. Localization of rat cytochrome p450 in various tissues and comparison of arachidonic acid metabolism by rat p450 with that by human p450 orthologs. Drug Metab Pharmacokinet 2005; 20:478-84.
41. Schwartzman ML, Omata K, Lin FM, Bhatt RK, Falck JR, Abraham NG. Detection of 20-hydroxyeicosatetraenoic acid in rat urine. Biochem Biophys Res Commun 1991; 180:445-9.
42. Omata K, Abraham NG, Escalante B, Schwartzman ML. Age-related changes in renal cytochrome p-450 arachidonic acid metabolism in spontaneously hypertensive rats. AJP 1992; 262:F8-16.
43. Omata K, Abraham NG, Schwartzman ML. Renal cytochrome p-450-arachidonic acid metabolism: Localization and hormonal regulation in SHR. AJP 1992; 262:F591-9.
44. Gebremedhin D, Ma YH, Imig JD, Harder DR, Roman RJ. Role of cytochrome p-450 in elevating renal vascular tone in spontaneously hypertensive rats. J Vasc Res 1993; 30:53-60.
45. Imig JD FJ, Gebremedhin D, Harder DR, Roman RJ. Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome p-450. Hypertension 1993; 22:357-64.
46. Omata K, Tsutsumi E, Sheu HL, Utsumi Y, Abe K. Effect of aging on renal cytochrome p450-dependent arachidonic acid metabolism in dahl rats. J Lipid Mediat 1993; 6:369-73.
47. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21:985-8.
48. Imig JD, Zou AP, Ortiz de Montellano PR, Sui Z, Roman RJ. Cytochrome p-450 inhibitors alter afferent arteriolar responses to elevations in pressure. AJP 1994; 266:H1879-85.
49. Lin F, Abraham NG, Schwartzman ML. Cytochrome p450 arachidonic acid omega-hydroxylation in the proximal tubule of the rat kidney. Ann N Y Acad Sci. 1994; 744:11-24.
50. Ma YH, Schwartzman ML, Roman RJ. Altered renal p-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. AJP 1994; 267:R579-89.
51. Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. AJP 1994; 266:F275-82.
52. Lin F, Rios A, Falck JR, Belosludtsev Y, Schwartzman ML. 20-hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. AJP 1995; 269:F806-16.
53. Lu M, Zhu Y, Balazy M, Reddy KM, Falck JR, Wang W. Effect of angiotensin II on the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol 1996; 108:537-47.
54. Schwartzman ML, da Silva JL, Lin F, Nishimura M, Abraham NG. Cytochrome p450 4a expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron.1996; 73:652-63.
55. Stec DE, Deng AY, Rapp JP, Roman RJ. Cytochrome p4504a genotype cosegregates with hypertension in Dahl S rats. Hypertension 1996; 27:564-8.
56. Stec DE, Trolliet MR, Krieger JE, Jacob HJ, Roman RJ. Renal cytochrome p4504a activity and salt sensitivity in spontaneously hypertensive rats. Hypertension 1996; 27:1329-36.
57. Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, Schwartzman ML. Cloning, sequencing, and cdnadirected expression of the rat renal cyp4a2: Arachidonic acid omega-hydroxylation and 11,12-epoxidation by cyp4a2 protein. Arch Biochem Biophys 1996; 336:240-50.
58. Zou AP, Drummond HA, Roman RJ. Role of 20-HET in elevating loop chloride reabsorption in Dahl SS/JR rats. Hypertension 1996; 27:631-5.
59. Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR, Roman RJ. Inhibition of 20-hete production contributes to the vascular responses to nitric oxide. Hypertension 1997; 29:320-5.
60. Kroetz DL, Huse LM, Thuresson A, Grillo MP. Developmentally regulated expression of the cyp4a genes in the spontaneously hypertensive rat kidney. Mol Pharmacol 1997; 52:362-372.
61. Stec DE, Mattson DL, Roman RJ. Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats. Hypertension 1997; 29:315-9.
62. Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. AJP 1998; 275:F370-8.
63. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome p-450 4a isoforms along the rat nephron. AJP 1998; 274:F395-404.
64. Su P, Kaushal KM, Kroetz DL. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. AJP 1998; 275:R426-38.
65. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the dahl salt-sensitive rat. Hypertension 1998; 31:225-31.
66. Alonso-Galicia M, Hudetz AG, Shen H, Harder DR, Roman RJ. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 1999; 30:2727-2734 discussion 2734.
67. Ito O, Roman RJ. Regulation of p-450 4a activity in the glomerulus of the rat. AJP 1999; 276:R1749-57.
68. Oyekan AO, Youseff T, Fulton D, Quilley J, McGiff JC. Renal cytochrome p450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 1999; 104:1131-7.
69. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M. Contribution of cytochrome p-450 4a1 and 4a2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. AJP 1999; 276:F246-53.
70. Li D, Belusa R, Nowicki S, Aperia A. Arachidonic acid metabolic pathways regulating activity of renal na(+)-k(+)-atpase are age dependent. AJP 2000; 278:F823-9.
71. Kunert MP, Roman RJ, Alonso-Galicia M, Falck JR, Lombard JH. Cytochrome p-450 v-hydroxylase: A potential o2 sensor in rat arterioles and skeletal muscle cells. AJP 2000; 280:H1840-5.
72. Gu R, Wei Y, Jiang H, Balazy M, Wang W. Role of 20-hete in mediating the effect of dietary K intake on the apical K channels in the mtal. AJP 2001; 280:F223-30.
73. Honeck H, Gross V, Erdmann B, Kargel E, Neunaber R, Milia AF, Schneider W, Luft FC, Schunck WH. Cytochrome p450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice. Hypertension 2000; 36:610-6.
74. Holla VR. Alterations in the regulation of androgen-sensitive cyp 4a monooxygenases cause hypertension. PNAS 2001; 98:5211-6.
75. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, Schunck WH. Mouse cyp4A isoforms: Enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochemical J 2007; 403:109-18.
76. Laethem RM, Laethem CL, Ding X, Koop DR. P-450 -dependent arachidonic acid metabolism in rabbit olfactory microsomes. J Pharmacol Exp Ther 1992; 262:433-8.
77. Macica C, Balazy M, Falck JR, Mioskowski C, Carro-ll MA. Characterization of cytochrome p-450-dependent arachidonic acid metabolism in rabbit intestine. Am J Physiol. 1993;265:G735-41
78. Carroll MA, Balazy M, Margiotta P, Huang DD, Falck JR, McGiff JC. Cytochrome p-450-dependent hetes: Profile of biological activity and stimulation by vasoactive peptides. AJP 1996; 271:R863-9.
79. Carroll MA, Balazy M, Huang DD, Rybalova S, Falck JR, McGiff JC. Cytochrome p450-derived renal hetes: Storage and release. Kidney Int 1997; 51:1696-702.
80. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 20-hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase ii-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U S A 1998; 95:12701-6.
81. Jacobs ER, Effros RM, Falck JR, Reddy KM, Campbell WB, Zhu D. Airway synthesis of 20-hydroxyeicosatetraenoic acid: Metabolism by cyclooxygenase to a bronchodilator. AJP 1999; 276:L280-8.
82. Quigley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-hete and 19(s)-hete on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol 2000; 278:F949-53
83. Zhu D, Birks EK, Dawson CA, Patel M, Falck JR, Presberg K, Roman RJ, Jacobs ER. Hypoxic pulmonary vasoconstriction is modified by p-450 metabolites. AJP 2000; 279:H1526-33.
84. Zhu D, Effros RM, Harder DR, Roman RJ, Jacobs ER. Tissue sources of cytochrome p450 4a and 20-HETE synthesis in rabbit lungs. Am J Respir Cell Mol Biol 1998; 19:121-8.
85. Kauser K, Clark JE, Masters BS, Ortiz de Montellano PR, Ma YH, Harder DR, Roman RJ. Inhibitors of cytochrome p-450 attenuate the myogenic response of dog renal arcuate arteries. Circ Res 1991; 68:1154-63.
86. Rosolowsky M, Falck JR, Campbell WB. Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim Biophys Acta 1996; 1300:143-50.
87. Hill E, Murphy RC. Quantitation of 20-hydroxy-5-,8,11,14-eicosatetraenoic acid (20-HETE) produced by human polymorphonuclear leukocytes using electron capture ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 1992; 21:249-53.
88. Prakash C, Zhang JY, Falck JR, Chauhan K, Blair IA. 20-hydroxyeicosatetraenoic acid is excreted as a glucuronide conjugate in human urine. Biochem Biophys Res Commun 1992; 185:728-33.
89. Zhu Y, Schieber EB, McGiff JC, Balazy M. Identification of arachidonate p-450 metabolites in human platelet phospholipids. Hypertension 1995; 25:854-9.
90. Birks EK, Bousamra M, Presberg K, Marsh JA, Effros RM, Jacobs ER. Human pulmonary arteries dilate to 20-hete, an endogenous eicosanoid of lung tissue. AJP 1997; 272:L823-9.
91. Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 1997; 100:1264-70.
92. Powell PK, Wolf I, Jin R, Lasker JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by p450 enzymes in human liver: Involvement of cyp4f2 and cyp4a11. J Pharmacol Exp Ther 1998; 285:1327-36.
93. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of cyp4f2 and cyp4a11. J Biol Chem 2000; 275:4118-26.
94. Watzer B, Reinalter S, Seyberth HW, Schweer H. Determination of free and glucuronide conjugated 20-hydroxyarachidonic acid (20-hete) in urine by gas chromatography /negative ion chemical ionization mass spectrometry. Prostaglandins Leukot Essent Fatty Acids 2000; 62:175-81.
95. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovascular Diabetology 2006; 23:5:4.
96. Flammer AJ, Lüscher TF. Three decades of endothelium research: From the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. Swiss Med Wkly. 2010; 1:140:w13122.
97. Strijdom H CN, Lochner A. Nitric oxide in the cardiovascular system: A simple molecule with complex actions. Cardiovasc J Afr 2009; 20:303-10.
98. Kompanowska-Jezierska E KM. Cytochrome p-450 metabolites in renal circulation and excretion--interaction with the nitric oxide (NO) system. J Physiol Pharmacol 2008; 59:137-49.
99. Sun CW, Falck JR, Okamoto H, Harder DR, Roman RJ. Role of cgmp versus 20-HETE in the vasodilator response to nitric oxide in rat cerebral arteries. AJP 2000; 279:H339-50.
100. Faraci FM, Sobey CG. Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation. Brain Res 1999; 821:368-73.
101. Oyekan AO, McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: Role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol 1998; 125:1065-73.
102. Cuez T, Korkmaz B, Buharalioglu CK, Sahan-Firat S, Falck J, Malik KU, Tunctan B. A synthetic analogue of 20-hete, 5,14-hedge, reverses endotoxininduced hypotension via increased 20-hete levels associated with decreased inos protein expression and vasodilator prostanoid production in rats. Basic Clin Pharmacol Toxicol 2010; 106:378-88.
103. Tunctan B, Korkmaz B, Buharalioglu CK, Firat SS, Anjaiah S, Falck J, Roman RJ, Malik KU. A 20-hydroxyeicosatetraenoic acid agonist, n-[20-hydroxyei-cosa-5(z),14(z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxintreated rats. Shock 2008; 30:329-35.
104. Tunctan B, Korkmaz B, Cuez T, Buharalioglu KC, Sahan-Firat S, Falck JR, Malik KU. Contribution of vasoactive eicosanoids and nitric oxide production to the effect of selective cyclooxygenase-2 inhibitor, ns-398, on endotoxin-induced hypotension in rats. BCPT 2010; 107:877-82.
105. Tunctan B, Yaghini FA, Estes A, Malik KU. Prostaglandins inhibit cytochrome p450 4a activity and contribute to endotoxin-induced hypotension in rats via nitric oxide production. Archives of Pharmacol Res 2008; 31:856-65.
106. Blanton A, Nsaif R, Hercule H, Oyekan A. Nitric oxide/cytochrome p450 interactions in cyclosporin a-induced effects in the rat. J Hypertens 2006; 24:1865-72.
107. Wang JS. Endothelial dysfunction and hypertension in rats transduced with cyp4a2 adenovirus. Circ Res 2006; 98:962-9.
108. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, Jr., Schwartzman ML. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via enos uncoupling. AJP 2008; 294:H1018-26.
109. Wang MH, Wang J, Chang HH, Zand BA, Jiang M, Nasjletti A, Laniado-Schwartzman M. Regulation of renal cyp4a expression and 20-hete synthesis by nitric oxide in pregnant rats. AJP 2003; 285:F295-302.
110. Toda N AK, Okamura T. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev 2007; 59:54-87.
111. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. AJP 2000; 279:F544-51.
112. Kohagura K, Arima S, Endo Y, Chiba Y, Ito O, Abe M, Omata K, Ito S. Involvement of cytochrome p450 metabolites in the vascular action of angiotensin II on the afferent arterioles. Hypertens Res 2001; 24:551-7.
113. Parmentier JH, Muthalif MM, Nishimoto AT, Malik KU. 20-hydroxyeicosatetraenoic acid mediates angiotensin ii-induced phospholipase d activation in vascular smooth muscle cells. Hypertension 2001; 37:623-9.
114. Chu ZM, Croft KD, Kingsbury DA, Falck JR, Reddy KM, Beilin LJ. Cytochrome p450 metabolites of arachidonic acid may be important mediators in angiotensin ii-induced vasoconstriction in the rat mesentery in vivo. Clin Sci (Lond). 2000; 98:277-82.
115. Frisbee JC, Falck JR, Lombard JH. Contribution of cytochrome p-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. AJP 2000; 278:H1517-26.
116. Fidelis P, Wilson L, Thomas K, Villalobos M, Oyekan AO. Renal function and vasomotor activity in mice lacking the cyp4a14 gene. Exp Biol Med 2010; 235:1365-74.
117. Yousif MH, Benter IF, Dunn KM, Dahly-Vernon AJ, Akhtar S, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes. Auton Autacoid Pharmacol 2009; 29:1-12.
118. Alonso-Galicia M, Maier KG, Greene AS, Cowley AW Jr., Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. AJP 2002; 283:R60-8.
119. Chabova VC, Kramer HJ, Vaneckova I, Vernerova Z, Eis V, Tesar V, Skaroupkova P, Thumova M, Schejbalova S, Huskova Z, Vanourkova Z, Kolsky A, Imig JD, Cervenka L. Effects of chronic cytochrome p-450 inhibition on the course of hypertension and end-organ damage in ren-2 transgenic rats. Vascul Pharmacol 2007; 47:145-59.
120. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008; 51:1379-85.
121. Elahi MM Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2009; 2:259-69.
122. Ward NC CK, Li C, Croft KD, Keaney JF Jr. Chronic ampk activation prevents 20-hete induced endothelial dysfunction. Clin Exp Pharmacol Physiol 2011; 38:328-33.
123. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome p450 4a expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 2007; 50:123-9.
124. Dunn KM, Renic M, Flasch AK, Harder DR, Falck J, Roman RJ. Elevated production of 20-hete in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. 2008; 295:H2455-65.
125. Nithipatikom K, Isbell MA, See WA, Campbell WB. Elevated 12-and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Lett 2006; 233:219-25.
126. Rivera J, Ward N, Hodgson J, Puddey IB, Falck JR, Croft KD. Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry. Clin Chem 2004; 50:224-6.
127. Ward NC. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004; 110:438-43.
128. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive supjects. Free Radic Biol Med 2005; 38:1032-6.
129. Tsai IJ CK, Puddey IB, Beilin LJ, Barden A. 20-hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. AJP 2011; 300:H194-200.
130. Yang X, Croft KD, Lee YP, Mori TA, Puddey IB, Sipsas S, Barden A, Swinny E, Hodgson JM. The effects of a lupin-enriched diet on oxidative stress and factors influencing vascular function in overweight supjects. Antioxid Redox Signal 2010; 13:1517-24.
131. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH. Functional variant of cyp4a11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111:63-9.
132. Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P, Pomarino A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Ziegler A, Erdmann J, Schunkert H. Association of a functional polymorphism in the cyp4a11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006; 24:1965-70.
133. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human cyp4f2 decreases 20-HETE production. Physiol Genomics 2007; 30:74-81.
134. Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M, Matsumoto K, Ozawa Y, Ma Y. Haplotype-based casecontrol study of the human cyp4f2 gene and essential hypertension in Japanese supjects. Hypertens Res 2008; 31:1719-26.
135. Laffer CL, Gainer JV, Waterman MR, Capdevila JH, Laniado-Schwartzman M, Nasjletti A, Brown NJ, Elijovich F. The t8590c polymorphism of cyp4a11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 2008; 51:767-72.
136. Liu H, Zhao Y, Nie D, Shi J, Fu L, Li Y, Yu D, Lu J. Association of a functional cytochrome p450 4f2 haplotype with urinary 20-hete and hypertension. J Am Soc Nephrology 2008; 19:714-21.
137. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD. A single nucleotide polymorphism in the cyp4f2 but not cyp4a11 gene is associated with increased 20-hete excretion and blood pressure. Hypertension 2008; 51:1393-8.
138. Zordoky BN, El-Kadi AO. Effect of cytochrome p450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010; 125:446-3.
139. Oyekan AO, McAward K, Conetta J, Rosenfeld L, McGiff JC. Endothelin-1 and cyp450 arachidonate metabolites interact to promote tissue injury in docasalt hypertension. Am J Physiol 1999; 276:R766-75.
140. Cambj-Sapunar L, Yu M, Harder DR, Roman RJ. Contribution of 5-hydroxytryptamine1b receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after suparachnoid hemorrhage. Stroke 2003; 34:1269-75.
141. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, Lee CR. Activation of the acute inflammatory response alters cytochrome p450 expression and eicosanoid metabolism. Drug Metab Dispos 2010; 39:22-9.
142. Anwar-Mohamed A, Zordoky BN, Aboutabl ME, El-Kadi AO. Alteration of cardiac cytochrome p450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 2010; 61:410-8.
143. Inoue R, Jensen LJ, Jian Z, Shi J, Hai L, Lurie AI, Henriksen FH, Salomonsson M, Morita H, Kawarabayashi Y, Mori M, Mori Y, Ito Y. Synergistic activation of vascular trpc6 channel by receptor and mechanical stimulation via phospholipase c/diacylglycerol and phospholipase a2/-hydroxylase/20-hete pathways. Circ Res 2009; 104:1399-409.
144. Frisbee JC RR, Krishna UM, Falck JR, Lombard JH. 20-HETE modulates myogenic response of skeletal muscle resistance arteries from hypertensive Dahl-SS rats. AJP 2001; 280:H1066-74.
145. Kaley G. Regulation of vascular tone: Role of 20-hete in the modulation of myogenic reactivity. Circ Res 2000; 87:4-5.
146. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome p450-derived eicosanoids: The neglected pathway in cancer. Cancer Metastasis Rev 2010; 29:723-35.
147. Yu W, Chen L, Yang YQ, Falck JR, Guo AM, Li Y, Yang J. Cytochrome p450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VGEF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol DOI: 10.1007/s00280-010-1521-8.